Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy.

Autor: Paulissen JHJ; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands. j.h.j.paulissen@umcg.nl.; Asc Academics, Groningen, The Netherlands. j.h.j.paulissen@umcg.nl., van Schoonhoven AV; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands.; Asc Academics, Groningen, The Netherlands., Olin E; AstraZeneca, Stockholm, Sweden., Postma AJ; Asc Academics, Groningen, The Netherlands., Mbanya Z; AstraZeneca Plc., Cambridge, UK., Dunton KJ; Daiichi Sankyo UK Ltd, Uxbridge, UK., Postma MJ; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands.; Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia., van Hulst M; Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands.; Department of Clinical Pharmacy and Toxicology, Martini Hospital, Groningen, The Netherlands., Freriks RD; Asc Academics, Groningen, The Netherlands.; Department of Health Technology and Services Research, TechMed Centre, University of Twente, Enschede, The Netherlands.

Publikováno v: Advances in therapy [Adv Ther] 2024 Nov 12. Date of Electronic Publication: 2024 Nov 12.

399P Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States

Autor: Modi, S., Byng, D., Zhang, S., Xiong, Y., Hunter, S., Struebing, A., Dunton, K., Mbanya, Z., Jacot, W.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S386-S386

HTA38 When and How Does RWE Impact HTA Outcomes in Oncology? A Qualitative Evaluation of Case Studies to Identify Drivers of RWE Acceptance Today and in the Future

Autor: Oswald, C, Anastasaki, E, Dunton, K, van Engen, A, Liljas, B, Mbanya, Z, Parry, D, Rosenlund, M, Szawara, P

Publikováno v: In Value in Health December 2022 25(12) Supplement:S303-S303

PHP306 - Tissue/Site Agnostic Regulatory Approval of Oncology Drugs: Are Htas Ready For A New Era In Personalised Medicine?

Autor: Sammon, C, Mbanya, Z, Sen Nikitas, F

Publikováno v: In Value in Health October-November 2017 20(9):A705-A705

PCN267 - Expanded Data Sets For Hta Decision-Making In Oncology: Do They Help To Achieve Positive Appraisals?

Autor: Chadda, S., Mbanya, Z., Gielen, V., Chandler, T.

Publikováno v: In Value in Health November 2014 17(7):A661-A661